PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will present more than 30 ...

Almost three-quarters of people incarcerated in Irish prisons have some form of substance addiction – but face long waits for ...

Background Diabetes mellitus (DM) is a common comorbidity in hypertrophic cardiomyopathy (HCM) and may exacerbate arrhythmic ...

ZEISS Medical Technology will showcase its latest enhancements in ophthalmic visualization and digital workflow innovation at ...

Transporeon, a Trimble Company, today announced the launch of its new Transport Planner tool, which delivers optimal ...

High-paying remote finance director jobs often involve managing accounting and financial control functions, establishing ...

Taysha Gene Therapies stock surges after FDA alignment on a pivotal Rett Syndrome study. Read the latest analysis on TSHA ...

Artificial intelligence and analytics platforms seek to help providers improve compliance, patient care experience and ...

Breakthrough Therapy designation granted based on FDA’s review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized FDA ...

Avacta is slated to present the final Phase Ia dose escalation data for our lead program, faridoxorubicin. This will be at ESMO 2025 in Berlin, a little bit later next month in October of 2025. There, ...